Selected Drugs Clear All
MultiCheck Results
- 11
Interactions
Avoid/Use Alternative |
||
|
K-Phos Original
(potassium acid phosphate) + Phillips' Milk of Magnesia
(magnesium hydroxide) |
||
Avoid/Use Alternativepotassium acid phosphate + magnesium hydroxide avoid combo or give phosphate 2h before: combo may decr. phosphate efficacy (absorption decreased) |
||
Monitor/Modify Tx |
||
|
Auvi-Q
(epinephrine (adrenaline)) + Cartia XT
(diltiazem) |
||
Monitor/Modify Txepinephrine + diltiazem monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Auvi-Q
(epinephrine (adrenaline)) + GaviLyte-C
(polyethylene glycol/ electrolytes) |
||
Monitor/Modify Txepinephrine + polyethylene glycol/ electrolytes monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects) |
||
|
Auvi-Q
(epinephrine (adrenaline)) + insulin aspart
(generic) |
||
Monitor/Modify Txepinephrine + insulin monitor glucose, potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias; may decr. antidiabetic agent efficacy (additive effects, antagonistic effects) |
||
|
Cartia XT
(diltiazem) + EpiPen
(epinephrine (adrenaline)) |
||
Monitor/Modify Txdiltiazem + epinephrine monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Cartia XT
(diltiazem) + Naphcon A
(pheniramine/ naphazoline ophthalmic) |
||
Monitor/Modify Txdiltiazem + naphazoline ophthalmic consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Eligard
(leuprolide) + insulin aspart
(generic) |
||
Monitor/Modify Txleuprolide + insulin monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects) |
||
|
EpiPen
(epinephrine (adrenaline)) + GaviLyte-C
(polyethylene glycol/ electrolytes) |
||
Monitor/Modify Txepinephrine + polyethylene glycol/ electrolytes monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects) |
||
|
EpiPen
(epinephrine (adrenaline)) + insulin aspart
(generic) |
||
Monitor/Modify Txepinephrine + insulin monitor glucose, potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias; may decr. antidiabetic agent efficacy (additive effects, antagonistic effects) |
||
|
GaviLyte-C
(polyethylene glycol/ electrolytes) + insulin aspart
(generic) |
||
Monitor/Modify Txpolyethylene glycol/ electrolytes + insulin monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects) |
||
Caution Advised |
||
|
Eligard
(leuprolide) + GaviLyte-C
(polyethylene glycol/ electrolytes) |
||
Caution Advisedleuprolide + polyethylene glycol/ electrolytes caution advised: combo may incr. risk of seizures (additive effects) |
||
Additional Considerations |
||
|
diltiazem
in Cartia XT
|
||
|
avoid combo with beverages or products containing ethanol and Cardizem CD, Cartia XT, some generic extended-release (ER) capsules; combo may incr. diltiazem release rate, levels, risk of adverse effects, decr. duration of efficacy |
||
|
polyethylene glycol/electrolytes
in GaviLyte-C
|
||
|
separate administration from other oral drugs by at least 1h; polyethylene glycol/electrolytes may decr. absorption of concomitant oral drugs |
||
|
epinephrine
in Auvi-Q, EpiPen
|
||
|
nasal epinephrine use: caution advised w/ nasal drugs, incl. subsequent nasal epinephrine doses, up to 2 wk after initial administration; nasal epinephrine may incr. systemic absorption of nasal drugs, risk of adverse effects |
||